AnDiConBio

China
Jiaxing, Zhejiang, China

Company profile

AnDiConBio company profile

developer of respiratory anti-infection drugs, offering high-potential, low-risk products like new anti-influenza and oral anti-new coronavirus.

Business identity

Operating status
Active
Company type
For Profit
Employee range
11-50 employees
Founded
2018-01-01, Year

Headquarters

Country code
CN
Continent
Asia

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
1
Total equity funding
$27.6M
Last funding
Series A / $27.6M / 2024-04-29
Last equity funding
Series A / $27.6M
Investors
10
Lead investors
2

Founders and investors

Lead investors

Huajin Avenue InvestmentHuajin Capital

Investors

Cowin CapitalHuajin CapitalJiaxing Xinchuang Venture CapitalSimcere PharmaWenzhou Capital